EGFR and lung cancer: Primary lung cancer cells bearing activating epidermal growth factor receptor (EGFR) mutations enter a reversible dormant state under hypoxic conditions, resulting in resistance to EGFR tyrosine kinase inhibitor treatment and irradiation [97].